Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(

Keywords

• *Carcinoma, Non-Small-Cell Lung
• Follow-Up Studies
• Humans
• *Lung Neoplasms/diagnosis/epidemiology/therapy
• *Small Cell Lung Carcinoma/diagnosis/epidemiology/therapy
• *Clinical Practice Guidelines
• *diagnosis
• *follow-up
• *small-cell lung cancer
• *treatment
• and/or lectures from Roche, Eli Lilly, Boehringer Ingelheim, AstraZeneca, Pfizer,
• Bristol Myers Squibb (BMS), Amgen, Novartis, Merck Sharp & Dohme (MSD), Takeda and
• PharmaMar
• research funding from BMS, AbbVie and Amgen. MF reports receipt of
• advisory board honoraria to institution from BMS, Takeda, AstraZeneca, Boehringer
• Ingelheim, MSD and Roche. AA reports receipt of honoraria for participation in
• advisory boards from AstraZeneca, Roche, MSD, BMS, Lilly, Takeda and Bayer
• research
• grant from BMS. BB reports receipt of grants/research support to institute from
• AbbVie, Amgen, AstraZeneca, BeiGene, Blueprint Medicines, BMS, Boehringer Ingelheim,
• Celgene, Cristal Therapeutics, Daiichi Sankyo, Eli Lilly, GlaxoSmithKline (GSK),
• Ignyta, IPSEN, Inivata, Janssen, Merck KGaA, MSD, Nektar, Onxeo, OSE
• Immunotherapeutics, Pfizer, PharmaMar, Roche-Genentech, Sanofi, Servier, Spectrum
• Pharmaceuticals, Takeda, Tiziana Pharma and Tolero Pharmaceuticals. CF-F reports
• participation in advisory boards for AstraZeneca
• research funding from MSD and
• AstraZeneca. LEH reports research funding to institution from Roche, Boehringer
• Ingelheim and AstraZeneca
• advisory board honoraria to institution from BMS, Lilly,
• Roche, Pfizer, Takeda, MSD, Amgen and Boehringer Ingelheim
• speaker fees from MSD
• travel/conference reimbursement from Roche and BMS
• participation in mentorship
• program funded by AstraZeneca
• fees for educational webinars from Quadia
• fees to
• institution for interview sessions from Roche. SL reports consulting activities for
• MSD, AstraZeneca, BMS, Bayer and Eli Lilly. SP reports receipt of honoraria to
• institute for consultancy, advisory boards and/or lectures from AbbVie, Amgen,
• AstraZeneca, Bayer, Biocartis, Bioinvent, Blueprint Medicines, Boehringer Ingelheim,
• BMS, Clovis, Daiichi Sankyo, Debiopharm, Eli Lilly, Roche, Foundation Medicine,
• Illumina, Janssen, MSD, Merck Serono, Merrimack, Mirati, Novartis, PharmaMar,
• Pfizer, Regeneron, Sanofi, Seattle Genetics, Takeda and Vaccibody
• institutional
• financial support for clinical trials from Amgen, AstraZeneca, Biodesix, Boehringer
• Ingelheim, BMS, Clovis, Roche, Illumina, MSD, Merck Serono, Novartis and Pfizer. NR
• reports receipt of speaker honoraria from MSD, BMS, Roche, Boehringer Ingelheim,
• Guardant Health, Pfizer, AbbVie, Ipsen, Novartis, AstraZeneca, Lilly, Takeda and
• Amgen
• fees for organising educational events from Amgen and Roche
• advisory panel
• honoraria from MSD, BMS, Roche, Boehringer Ingelheim, Guardant Health, Pfizer,
• AbbVie, Ipsen, Novartis, AstraZeneca, Lilly, Takeda and Amgen
• sponsorship to attend
• scientific meetings from Boehringer Ingelheim, MSD and Roche
• research grants from
• Novartis and Pfizer. CMR reports consultancy for AbbVie, Amgen, Ascentage,
• AstraZeneca, Bicycle, Celgene, Daiichi Sankyo, Genentech/Roche, Ipsen, Jazz, Lilly,
• Pfizer, PharmaMar, Syros and Vavotek
• serves on scientific advisory boards for
• Bridge Medicines and Harpoon Therapeutics. DDR reports receipt of research grants to
• institute from BMS, AstraZeneca and Boehringer Ingelheim
• advisory board honoraria
• to institute from BMS, AstraZeneca, Boehringer Ingelheim and Philips
• funding to
• institute for investigator-initiated study from Olink. PEVS reports board membership
• of IASLC
• treasurer of BACTS
• fees to institution for serving as an external expert
• for AstraZeneca, MSD and National Cancer Institute, France. JV reports receipt of
• advisory board honoraria and/or lecture fees from Boehringer Ingelheim, AstraZeneca,
• MSD, Novartis, Roche, Pfizer and BMS
• research grant to institute from MSD. MR
• reports receipt of honoraria for lectures and consultancy from Amgen, AstraZeneca,
• BMS, Boehringer Ingelheim, Lilly, Merck, MSD, Novartis, Pfizer, Roche and Samsung
• funding for academic research from BMS and Boehringer Ingelheim.